{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["53(5)"],"submitter":["Ul Haq MZ"],"pubmed_abstract":["<h4>Introduction</h4>Since late 2019, COVID-19 has had a catastrophic impact on public health. Ensitrelvir, a new antiviral targeting the SARS-CoV-2 main protease, has reduced viral replication and disease severity. This meta-analysis and systematic review assessed Ensitrelvir's efficacy and safety in patients with mild-to-moderate COVID-19 symptoms.<h4>Methods</h4>A comprehensive search was conducted in PubMed (Medline), Scopus, Embase, and CENTRAL up to July 2024 to retrieve randomized controlled trials (RCTs) comparing Ensitrelvir to placebo in adults with mild to moderate, RT-PCR-confirmed COVID-19. Outcomes were assessed at standardized time points, with viral RNA measured at day 4. Mean differences (MD) for continuous outcomes and risk ratios (RR) for binary outcomes, both with 95% c"],"journal":["Infection"],"pagination":["1645-1661"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12460428"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of Ensitrelvir in asymptomatic or mild to moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials."],"pmcid":["PMC12460428"],"pubmed_authors":["Ashraf S","Shah MSU","Goyal A","Saeed H","Ul Haq MZ","Ansari MA","Sulaiman SA","Shaukat A","Fatima L","Basaria AAA","Daoud M"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of Ensitrelvir in asymptomatic or mild to moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials.","description":"<h4>Introduction</h4>Since late 2019, COVID-19 has had a catastrophic impact on public health. Ensitrelvir, a new antiviral targeting the SARS-CoV-2 main protease, has reduced viral replication and disease severity. This meta-analysis and systematic review assessed Ensitrelvir's efficacy and safety in patients with mild-to-moderate COVID-19 symptoms.<h4>Methods</h4>A comprehensive search was conducted in PubMed (Medline), Scopus, Embase, and CENTRAL up to July 2024 to retrieve randomized controlled trials (RCTs) comparing Ensitrelvir to placebo in adults with mild to moderate, RT-PCR-confirmed COVID-19. Outcomes were assessed at standardized time points, with viral RNA measured at day 4. Mean differences (MD) for continuous outcomes and risk ratios (RR) for binary outcomes, both with 95% c","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-03T19:51:35.173Z","creation":"2026-05-01T03:10:56.741Z"},"accession":"S-EPMC12460428","cross_references":{"pubmed":["40742497"],"doi":["10.1007/s15010-025-02582-0"]}}